As of 2024-09-19, the EV/EBITDA ratio of Heron Therapeutics Inc (HRTX) is -9.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HRTX's latest enterprise value is 426.97 mil USD. HRTX's TTM EBITDA according to its financial statements is -47.27 mil USD. Dividing these 2 quantities gives us the above HRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.0x - 22.2x | 16.4x |
| Forward P/E multiples | 18.7x - 29.0x | 22.6x |
| Fair Price | (6.71) - (7.77) | (6.96) |
| Upside | -443.9% - -498.5% | -456.8% |
| Date | EV/EBITDA |
| 2024-09-18 | -9.03 |
| 2024-09-17 | -8.87 |
| 2024-09-16 | -8.65 |
| 2024-09-13 | -8.78 |
| 2024-09-12 | -8.68 |
| 2024-09-11 | -8.58 |
| 2024-09-10 | -8.62 |
| 2024-09-09 | -8.58 |
| 2024-09-06 | -8.55 |
| 2024-09-05 | -8.55 |
| 2024-09-04 | -8.45 |
| 2024-09-03 | -8.33 |
| 2024-08-30 | -8.97 |
| 2024-08-29 | -8.97 |
| 2024-08-28 | -8.97 |
| 2024-08-27 | -8.97 |
| 2024-08-26 | -9.13 |
| 2024-08-23 | -9.03 |
| 2024-08-22 | -8.78 |
| 2024-08-21 | -9.13 |
| 2024-08-20 | -8.84 |
| 2024-08-19 | -9.13 |
| 2024-08-16 | -8.97 |
| 2024-08-15 | -9.03 |
| 2024-08-14 | -8.74 |
| 2024-08-13 | -9.32 |
| 2024-08-12 | -9.35 |
| 2024-08-09 | -9.13 |
| 2024-08-08 | -9.63 |
| 2024-08-07 | -9.19 |
| 2024-08-06 | -11.34 |
| 2024-08-05 | -11.21 |
| 2024-08-02 | -11.49 |
| 2024-08-01 | -11.79 |
| 2024-07-31 | -12.31 |
| 2024-07-30 | -11.79 |
| 2024-07-29 | -12.18 |
| 2024-07-26 | -12.56 |
| 2024-07-25 | -12.72 |
| 2024-07-24 | -12.88 |
| 2024-07-23 | -12.95 |
| 2024-07-22 | -13.04 |
| 2024-07-19 | -13.20 |
| 2024-07-18 | -13.46 |
| 2024-07-17 | -14.01 |
| 2024-07-16 | -14.55 |
| 2024-07-15 | -13.40 |
| 2024-07-12 | -13.17 |
| 2024-07-11 | -13.40 |
| 2024-07-10 | -12.53 |